Patents Assigned to Merck Sharp & Dohme
-
Publication number: 20240174679Abstract: The present invention is directed to certain (hetero)aroyl 4-aminopyrazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.Type: ApplicationFiled: March 14, 2022Publication date: May 30, 2024Applicant: Merck Sharp & Dohme LLCInventors: Kaleen Konrad Childers, J. Michael Ellis, Peter J. Fuller, Hakan Gunaydin, Jack D. Scott, Haiqun Tang, Charles S. Yeung
-
Patent number: 11995593Abstract: An adaptive risk management application retrieves data corresponding to an asset. The asset is a computing device or software application of an enterprise system. The adaptive risk management application identifies a set of vulnerabilities of the asset. The adaptive risk management application determines, for each identified vulnerability, a likelihood of a threat actor successfully exploiting the vulnerability. The adaptive risk management application determines, based on the likelihoods, a risk score for the asset. The adaptive risk management application sends the risk score for display.Type: GrantFiled: November 19, 2019Date of Patent: May 28, 2024Assignee: Merck Sharp & Dohme LLCInventors: Mark Joseph Risoldi, Sethuraman Balasubramanian
-
Patent number: 11993602Abstract: The present invention provides a compound of Formula (I) Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.Type: GrantFiled: August 5, 2019Date of Patent: May 28, 2024Assignee: Merck Sharp & Dohme LLCInventors: David Witter, Shuhei Kawamura, Michelle Machacek, Ryan Quiroz, Michael H. Reutershan, Sebastian Schneider, Phieng Siliphaivanh, Yingchun Ye, Charles S. Yeung
-
Patent number: 11992521Abstract: A method is described for producing a pneumococcal capsular polysaccharide protein conjugate in which one or more activated pneumococcal polysaccharides of particular pneumococcal serotypes and carrier protein are separately lyophilized, the separately lyophilized polysaccharides and carrier protein are separately reconstituted in an organic solvent, and the reconstituted polysaccharide and carrier protein are then combined together by Tee-mixing and conjugated together to produce polysaccharide carrier protein conjugates. A plurality of conjugates, each comprising polysaccharides of a particular serotype, may be used to produce multivalent pneumococcal immunogenic compositions having a combination of conjugates for use in vaccines.Type: GrantFiled: October 25, 2022Date of Patent: May 28, 2024Assignee: Merck Sharp & Dohme LLCInventors: Patrick Leonard Ahl, Akhilesh Bhambhani, Christopher Jon Farrell, Patrick McHugh, Morrisa C. Jones, Daniel D. Roth, Jessica R. Sinacola, Justin Stanbro, Matthew P. Watson, Emily Wen, Michael A. Winters
-
Patent number: 11992489Abstract: Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder.Type: GrantFiled: August 12, 2019Date of Patent: May 28, 2024Assignee: Merck Sharp & Dohme LLCInventors: Dane Clausen, Xavier Fradera, Yongxin Han, Alexander Pasternak, Li Xiao, Hongjun Zhang
-
Publication number: 20240158754Abstract: The present invention provides a method of reducing a high mannose glycan (HMG) content of a protein (e.g., monoclonal antibody) expressed during a mammalian cell culture (e.g., CHO cell culture) process, as well as a cell culture medium for reducing an HMG content of a protein (e.g., monoclonal antibody) expressed during a mammalian cell culture (e.g., CHO cell culture) process.Type: ApplicationFiled: March 3, 2022Publication date: May 16, 2024Applicant: MERCK SHARP & DOHME LLCInventors: Gaurav Chauhan, Wai Lam Wong Ling
-
Publication number: 20240158388Abstract: The present invention is directed to pro drugs of 2-methyl-N-((5-methyl-1,3,4-thiadiazol-2-yl)methyl)-6-(((1S,2S)-2-(5-methylpyridin-2-yl)cyclopropyl)methoxy)pyrimidin-4-amine which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 10 (PDE10). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.Type: ApplicationFiled: December 13, 2023Publication date: May 16, 2024Applicant: Merck Sharp & Dohme LLCInventors: Sachin Mittal, Jason W. Skudlarek, Izzat T. Raheem
-
Patent number: 11980623Abstract: The present invention is directed to a pharmaceutical composition comprising the compound suvorexant, or a pharmaceutically acceptable salt thereof, a concentration-enhancing polymer, and optionally a pharmaceutically acceptable surfactant.Type: GrantFiled: September 14, 2021Date of Patent: May 14, 2024Assignee: Merck Sharp & Dohme LLCInventors: Paul A. Harmon, Narayan Variankaval, Michael Lowinger, Chad David Brown, Francis Flanagan
-
Patent number: 11981701Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts thereof, which are PRMT5 inhibitors.Type: GrantFiled: August 5, 2019Date of Patent: May 14, 2024Assignee: Merck Sharp & Dohme LLCInventors: Jongwon Lim, Michelle Machacek, Michael H. Reutershan, Sebastian Schneider
-
Patent number: 11981726Abstract: The present invention relates to monoclonal antibodies which have high anti-RSV neutralizing titers. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. The invention yet further provides for diagnostic, prophylactic and therapeutic methods employing the antibodies and nucleic acids of the invention, particularly as a passive immunotherapy agent in infants and the elderly.Type: GrantFiled: December 13, 2022Date of Patent: May 14, 2024Assignee: Merck Sharp & Dohme LLCInventors: Kalpit A. Vora, Kara S. Cox, Aimin Tang, Zhifeng Chen, Daniel DiStefano, Lan Zhang, Hua-Poo Su
-
Publication number: 20240150729Abstract: The instant invention discloses a closed-system, serum-free, microcarrier-based up-stream process to produce dengue virus. The process comprises a closed-system cell expansion comprising cell passages taking place in closed-system containers. These cell expansions represent a closed process, with replacement media, a cell-detachment agent, and quench medium added though sterile, weldable tubing (a closed-system environment) to eliminate all open aseptic processing following the initial vial thaw of the adherent cells. The viral production takes place in a closed-system bioreactor in adherent cell culture grown on microcarriers providing sufficient cell mass to support the production of dengue virus.Type: ApplicationFiled: March 17, 2022Publication date: May 9, 2024Applicant: Merck Sharp & Dohme LLCInventors: Pooja Chadha, Kent Harley Hamaker, Shannon Haughney, Samantha J. Marrone, Christopher Ton, Igor Zabrodin
-
COMPOSITIONS AND METHODS FOR TREATING CANCER WITH SUBCUTANEOUS ADMINISTRATION OF ANTI-PD1 ANTIBODIES
Publication number: 20240150467Abstract: The invention relates to compositions and methods for treating cancer in a patient comprising subcutaneously administering a PD-1 antagonist, e.g., an anti-PD-1 antibody (e.g. pembrolizumab), or antigen binding fragment thereof, with or without hyaluronidase every six weeks, in specific amounts to the patient. In specific embodiments, the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 600 mg to about 1000 mg. In specific embodiments, the administration occurs about every three weeks, and the amount of anti-PD-1 antibody, or antigen binding fragment thereof, is about 300 mg to about 500 mg. In certain embodiments, the PD-1 antagonist is pembrolizumab, or an antigen binding fragment thereof. Also provided are compositions and kits formulated for subcutaneous administration comprising a particular dosage of an anti-PD-1 antibody, or antigen-binding fragment thereof, and uses thereof for treating cancer.Type: ApplicationFiled: October 11, 2023Publication date: May 9, 2024Applicant: Merck Sharp & Dohme LLCInventors: Omobolaji O. Akala, Carolina De Miranda Silva, Elliot Keith Chartash, Mallika Lala, III, Kapil Mayawala -
Patent number: 11975100Abstract: A process for preparing and isolating pharmaceutical active ingredient particles having a particle size of between about 0.1 and 30 microns, wherein a slurry comprising the active ingredient and one or more pharmaceutically acceptable excipients is fed into a thin film evaporator under suitable conditions for less than 10 minutes sufficient to generate solid matrix particles comprising active ingredient and one or more excipients, wherein the particles have less than 5% residual solvent.Type: GrantFiled: September 29, 2021Date of Patent: May 7, 2024Assignee: Merck Sharp & Dohme LLCInventors: Luke R. Schenck, David J. Lamberto, Joseph L. Kukura, II, Francisco J. Guzman, Aaron Cote, Athanas Koynov
-
Patent number: 11976069Abstract: The present invention relates to Compounds of Formula I and Ia and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, X, A and B are as defined herein. The present invention also relates to compositions comprising at least one compound of Formula I or Ia, and methods of using the compounds of Formula I or Ia for treating or preventing HIV infection in a subject.Type: GrantFiled: March 16, 2020Date of Patent: May 7, 2024Assignee: Merck Sharp & Dohme LLCInventors: Wensheng Yu, Joseph A. Kozlowski, Dane James Clausen, Jian Liu, James Fells
-
Patent number: 11976061Abstract: Invented are compounds of Formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.Type: GrantFiled: October 6, 2021Date of Patent: May 7, 2024Assignee: Merck Sharp & Dohme, LLCInventors: Yeon-Hee Lim, Eric R. Ashley, Jianming Bao, Chen Cheng, James P. Roane, Emma Helen Southgate
-
Publication number: 20240140938Abstract: Invented are compounds of formula I and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are DGAT2 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat hepatic steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, type-2 diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, cognitive decline, dementia, cardiorenal diseases such as chronic kidney diseases and heart failure and related diseases and conditions, comprising administering a compound of Formula I to a patient in need thereof.Type: ApplicationFiled: December 17, 2021Publication date: May 2, 2024Applicant: Merck Sharp & Dohme LLCInventors: Jianming Bao, Chen Cheng, Faben A. Cruz, Yeon-Hee Lim, Cedric L. Hugelshofer, Jinlong Jiang, Victor W. Mak, Emma Helen Southgate
-
Publication number: 20240142356Abstract: In some embodiments, a reciprocal injection device includes a platform having a motor, a gearbox operatively coupled to the motor, an actuation slide driven by the motor, a pair of clamp fixtures for supporting two syringes, a pair of axially translatable syringe plunger fixtures, and an interface in communication with the platform and configured and arranged to actuate the motor.Type: ApplicationFiled: October 19, 2023Publication date: May 2, 2024Applicant: Merck Sharp & Dohme LLCInventors: Guangli Hu, Steven Carl Persak, Yongchao Su, Edward Yeung
-
Publication number: 20240140920Abstract: The present invention relates to efficient synthetic processes useful in the preparation of uridine, which is useful in the production of nucleosides and nucleotides that may be active as antiviral agents, as well as compositions and methods thereof.Type: ApplicationFiled: December 17, 2021Publication date: May 2, 2024Applicant: Merck Sharp & Dohme LLCInventors: Tamas Benkovics, Anna Fryszkowska, Mark A. Huffman, Tetsuji Itoh, Kevin M. Maloney, John McIntosh, Grant S. Murphy
-
Publication number: 20240139303Abstract: The present invention provides immunogenic compositions having one or more polysaccharide-protein conjugates in which one or more polysaccharides from Streptococcus pneumoniae bacterial capsules are conjugated to a carrier protein in an aprotic solvent such as dimethylsulfoxide (DMSO). The present invention also provides methods for providing an enhanced immune response to a pneumococcal polysaccharide protein conjugate vaccine comprising administering to a human subject an immunogenic composition comprising polysaccharide-protein conjugates prepared in DMSO conditions.Type: ApplicationFiled: June 22, 2023Publication date: May 2, 2024Applicant: Merck Sharp & Dohme LLCInventors: Julie M. Skinner, Patrick McHugh
-
Patent number: 11970479Abstract: The present invention is directed to cinnolinyl and quinolinyl pyrazol-4-yl-pyridine compounds which are allosteric modulators of the M4 muscarinic acetylcholine receptor. The present invention is also directed to uses of the compounds described herein in the potential treatment or prevention of neurological and psychiatric disorders and diseases in which M4 muscarinic acetylcholine receptors are involved. The present invention is also directed to compositions comprising these compounds. The present invention is also directed to uses of these compositions in the potential prevention or treatment of such diseases in which M4 muscarinic acetylcholine receptors are involved.Type: GrantFiled: October 24, 2019Date of Patent: April 30, 2024Assignees: Merck Sharp & Dohme LLC, MSD R&D (China) Co. LTD.Inventors: John J. Acton, III, Melissa Egbertson, Xiaolei Gao, Scott T. Harrison, Timothy J. Henderson, Michael Man-Chu Lo, Robert D. Mazzola, Jr., Zhaoyang Meng, James Mulhearn, Vanessa L. Rada, Jeffrey W. Schubert, Oleg B. Selyutin, David M. Tellers, Ling Tong, Fengqi Zhang, Jianming Bao, Chunsing Li